ARYA Sciences Acquisition Corp. IV, Amicus Therapeutics Report Mutual Termination of Business Collaboration for Amicus’ Gene Therapy Unit

ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors, today announced that, due to existing market conditions, it has jointly agreed with Amicus Therapeutics, Inc. (NASDAQ :FOLD) (“Amicus”) to terminate the previously announced Business Combination Agreement (the “Business Combination Agreement”) with immediate effect.

“While this is not the outcome we had hoped for, ARYA IV still has over a year to identify and execute a business combination transaction, and the ARYA IV team believes it is well positioned to identify and pursue an opportunity that meets its key investment criteria and that can deliver shareholder value over this period,” said Adam Stone, CEO. The deadline for termination of ARYA IV is March 2, 2023 (unless such deadline is extended in accordance with the governing documents of ARYA IV).

Neither party will be obligated to pay the other any termination fee as a result of the joint decision to terminate the Business Combination Agreement.